Uncategorized

ASCO: Akeso’s VEGF/PD-1 boosts lung cancer survival, relieving pressure on US partner Summit

Published

on

Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version